

## **Application of bevacizumab (avastin) in patients with exudative age-related macular degeneration and in patients with diffuse diabetic macular edema**

Authors: Dorota Palenga-Pydyn, Joanna Bartela, Iwona Laudańska-Olszewska, Lodz, Poland

### **Advantages:**

Application of Bevacizumab is a new tool in ARMD and diffuses diabetic macular edema treatment. As it seems after 20 months of use it is effective.

### **Methods:**

The study included 20 patients with exudative age-related macular degeneration and 15 patients with diffuse diabetic macular edema. The diagnosis was confirmed by fluorescein angiography. At the beginning of observation BCVA, eye fundus examination with indirect ophthalmoscopy, fluorescein angiography, and OCT were performed. Each patient had injection of 1.25 mg of Bevacizumab into the vitreous cavity three times with a one-month interval. Every four weeks BCVA and OCT were performed in each patient.

### **Effectiveness / Safety:**

In both groups of patients anatomical and functional improvements were observed. We did not observe any local or systemic side effects.

### **Take home message:**

Try to apply Bevacizumab in ARMD and macular diabetic edema patients despite the fact that it is an « off label » drug.